Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelyrin Inc (NQ: SLRN )

4.560 +0.230 (+5.31%)
Streaming Delayed Price Updated: 11:08 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acelyrin Inc

< Previous 1 2 3 4 5 6 Next >
NASDAQ:SLRN Shareholder Notice: Investigation over Possible Securities Laws Violations by Acelyrin, Inc.
San Diego, CA -- (SBWIRE) -- 10/06/2023 -- An investigation was announced over potential securities laws violations by Acelyrin, Inc in connection with certain financial statements. 
Via SBWire
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
From Acelyrin, Inc.
Via GlobeNewswire
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Acelyrin Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Why Acelyrin Stock Plummeted 59% This Week
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate. 
Via The Motley Fool
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
Despite Trial Setback For Acelyrin's Lead Program, Analyst Shows Optimism
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe Hidradenitis Suppurativa (HS).  
Via Benzinga
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded up 0.11% to 34,702.55 while the NASDAQ fell 0.86% to 13,797.73.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
Dow Turns Higher; Oracle Shares Tumble After Q1 Results
U.S. stocks traded mixed midway through trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.22% to 34,740.15 while the NASDAQ fell 0.55% to 13,841.02. The S&P 500, also fell,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
A competitor's clinical trial stumble may be benefiting MoonLake. 
Via The Motley Fool
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
Benzinga 
Via Benzinga
Is American Battery Technology Company (ABML) Stock Really Up 1,300%?
American Battery Technology Company (ABML) stock surprised investors Tuesday morning when it appeared to rocketing more than 1,300% higher. 
Via InvestorPlace
Dow Falls 75 Points; US Small Business Optimism Drops In August
U.S. stocks traded lower this morning, with the Dow Jones falling around 75 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.22% to 34,587.58 while the NASDAQ fell 0.21%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Datasea (DTSS) Stock Down 39% Today?
Datasea (DTSS) stock is falling on Tuesday after the company announced a proposed public stock offering priced at 40 cents per share. 
Via InvestorPlace
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
The companies are both working on treatments for a rare skin disease. 
Via Investor's Business Daily
Why Is Acelyrin (SLRN) Stock Down 58% Today?
Acelyrin (SLRN) stock is falling hard on Tuesday after the biopharma company announced lackluster clinical trial results. 
Via InvestorPlace
Why Is Skin Disorders Focused Acelyrin Stock Trading Lower Today?
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe  
Via Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
Oracle, Sight Sciences And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Acelyrin, Inc.
Via GlobeNewswire
The Truth About IPO Investing
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
Via Benzinga
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.